Genentech, Biogen Idec file declaratory relief complaint against GSK regarding Arzerra

Genmab A/S (Other OTC:GNMSF) (Copenhagen:GEN) announced today that on March 23, 2010 Genentech, Inc. and Biogen Idec, Inc. filed a declaratory relief complaint at the US District Court, Southern District of California against Genmab's collaboration partner GlaxoSmithKline (GSK) for patent infringement under US patent No 7,682,612 based on GSK's manufacture, marketing and sale of Arzerra™ in the United States for the treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL).

US patent No 7,682,612 was issued to Genentech, Inc. and Biogen Idec, Inc. on March 23, 2010 and contains a claim to a method of treating CLL with anti-CD20 antibodies, wherein the method does not comprise treatment with radiolabeled anti-CD20 antibodies.

Genmab will, in collaboration with GSK, assess and analyze the claims under the initiated legal action and determine the appropriate action in response to the complaint.


Genmab A/S


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Study suggests anti-PF4 antibodies may play a role in the severe multiorgan disease manifestations of COVID-19